Prof. PeptideProf. Peptide

CoQ10

Longevity

Last reviewed: May 26, 2026

Also Known As: Coenzyme Q10, ubiquinol (reduced form), ubiquinone (oxidized form), CoQ, mitoquinol

Supplement Class: Mitochondrial electron carrier / fat-soluble antioxidant / vitamin-like compound

Evidence Tier: Strong — the Q-SYMBIO heart failure RCT (Mortensen et al. 2014, n=420, 2-year mortality reduction); KiSel-10 (Alehagen et al. 2013, n=443, 54% CV mortality reduction over 4 years); Banach et al. 2015's meta-analysis for statin myopathy; Lafuente et al. 2013's meta-analysis for male fertility — hard cardiovascular-outcomes evidence unusually strong for a supplement.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is CoQ10?

Coenzyme Q10 (CoQ10) is a fat-soluble, vitamin-like compound present in virtually every cell of the human body, hence its alternate name, ubiquinone (from "ubiquitous"). It plays two roles: it is the essential mobile electron carrier in the mitochondrial electron transport chain (shuttling electrons between Complex I/II and Complex III to drive ATP synthesis), and in its reduced form (ubiquinol) it is one of the more important endogenous fat-soluble antioxidants. CoQ10 levels are reported to decline with age and are further reduced by statin medications, both via the shared HMG-CoA reductase / mevalonate pathway. The supplement evidence base is unusually strong: Q-SYMBIO (Mortensen et al. 2014) reports a 2-year cardiovascular mortality reduction with 300 mg/day in heart failure patients, and KiSel-10 (Alehagen et al. 2013) reports CoQ10 plus selenium reduced cardiovascular mortality by 54% in elderly adults over 4 years. Statin-myopathy evidence (Banach et al. 2015's meta-analysis) is positive. CoQ10 is discussed alongside mitochondrial peptides like MOTS-c given the mechanisms' operation on different layers of mitochondrial bioenergetics.

Reported benefits:

  • Reduced cardiovascular mortality in chronic heart failure (Q-SYMBIO, 2-year follow-up)
  • 54% cardiovascular mortality reduction with CoQ10 plus selenium in elderly adults (KiSel-10, 4-year follow-up)
  • Reduced statin-induced muscle symptoms (Banach et al. 2015's meta-analysis)
  • Improved sperm concentration, motility, and morphology in subfertile men (Lafuente et al. 2013's meta-analysis)
  • Migraine prophylaxis, roughly 25–30% frequency reduction at 300 mg/day
  • Essential cofactor for mitochondrial ATP synthesis via the electron transport chain
  • Fat-soluble antioxidant protecting mitochondrial membranes and circulating LDL

Common dose: 100–200 mg/day ubiquinol (or 200–300 mg ubiquinone) for general health and age-related maintenance; 300 mg/day ubiquinone for clinical heart failure adjunct (the Q-SYMBIO protocol); 100–200 mg/day for statin myopathy; 300–400 mg/day for fertility, migraine, or mitochondrial disease. With fat-containing meals.

Reported safety considerations: A modest interaction with warfarin (structural similarity to vitamin K) warranting INR monitoring. Mild blood-pressure lowering, relevant for users on antihypertensive medication. No negative interaction with statins — CoQ10 is generally regarded as a beneficial coadministration given statin-induced CoQ10 depletion.

On this page
  1. 1.How does CoQ10 work?
  2. 2.What does the evidence say CoQ10 does?
  3. 3.How is CoQ10 dosed?
  4. 4.How CoQ10 is taken
  5. 5.What does CoQ10 stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about CoQ10
  8. 8.Product-quality considerations
  9. 9.CoQ10 FAQ
  10. 10.References
  11. 11.Published Studies

How does CoQ10 work?

CoQ10 is reported to work through two parallel mechanisms that converge on cellular energy production and mitochondrial protection. As an essential mobile electron carrier in the mitochondrial electron transport chain, it shuttles electrons between Complex I/II and Complex III — without adequate CoQ10, ATP synthesis is impaired. As a fat-soluble antioxidant, it protects mitochondrial membranes, neuronal membranes, and circulating LDL from oxidative damage. Both arms decline with age and with statin use.

  1. Electron transport chain shuttle. CoQ10 (in both ubiquinone and ubiquinol forms) is reported to cycle between oxidized and reduced states as it carries electrons from Complex I and Complex II of the electron transport chain to Complex III. This electron flow generates the proton gradient across the inner mitochondrial membrane that drives ATP synthesis; CoQ10 deficiency is discussed as directly impairing mitochondrial ATP production.
  2. Fat-soluble membrane antioxidant. Ubiquinol (the reduced form) is one of the few endogenous lipid-soluble antioxidants — it is reported to protect mitochondrial inner-membrane phospholipids, neuronal cell membranes, and circulating LDL particles from oxidative damage, and to regenerate vitamin E (α-tocopherol) and support vitamin C recycling.
  3. Statin–CoQ10 interaction. Statins inhibit HMG-CoA reductase — the enzyme upstream of both cholesterol synthesis and the mevalonate pathway that produces endogenous CoQ10. Chronic statin use is reported to reduce CoQ10 levels by roughly 30–40%, discussed as contributing to statin-induced myopathy in a subset of users — the strongest mechanistic case for CoQ10 supplementation in statin users.
  4. Cardiac tissue concentration. The heart has the highest CoQ10 concentration of any organ, reflecting cardiac muscle's extraordinary energy demand. CoQ10 depletion is implicated in cardiac dysfunction at the cellular bioenergetic level, discussed as the mechanistic basis for the heart-failure trial results.
  5. Age-related decline. Endogenous CoQ10 production is reported to decline with age, particularly after 40, with tissue concentrations dropping in heart, skeletal muscle, and liver. Whether this decline drives age-related dysfunction or accompanies it is debated; supplementation can correct the decline toward younger-adult levels.

What does the evidence say CoQ10 does?

CoQ10 has one of the stronger cardiovascular-outcomes RCT bases of any supplement reviewed for this site. The Q-SYMBIO heart failure trial is particularly strong evidence — a hard-endpoint mortality trial with meaningful effect sizes. Secondary evidence covers statin myopathy, fertility, migraine prophylaxis, and neurodegenerative diseases. The general anti-aging case in healthy adults is weaker than the clinical-population case.

  1. Heart failure outcomes (Strong). Q-SYMBIO (n=420, 2 years) reports significant reductions in cardiovascular mortality and major adverse cardiovascular events with 300 mg/day in chronic heart failure. KiSel-10 (n=443, 4 years) reports combined CoQ10 plus selenium reduced cardiovascular mortality 54% in elderly adults — hard-endpoint outcomes data, unusual for a supplement.
  2. Statin-induced muscle symptoms (Moderate). Banach et al. 2015's meta-analysis (6 RCTs, n=302) reports significant reductions in muscle pain, weakness, cramps, and tiredness with CoQ10, with effect sizes described as modest and the signal not universal across all trials.
  3. Sperm and egg quality (Moderate). Lafuente et al. 2013's meta-analysis (3 RCTs, n=312) reports significant improvements in sperm concentration, motility, and morphology. Female fertility evidence is smaller but suggests improved ovarian response in older reproductive-age women.
  4. Migraine prophylaxis (Moderate). Several RCTs report CoQ10 reduces migraine frequency by roughly 25–30% with 300 mg/day for 3 months — a modest effect, discussed as a reasonable adjunct in migraine management protocols.
  5. Neurodegenerative diseases (Mixed). Trials in Parkinson's disease, Huntington's, and ALS have reported mixed results, with some positive signals and some null findings. The mechanistic rationale is discussed as strong; clinical efficacy at the doses tested is unresolved.
  6. Exercise performance and recovery (Weak/Modest). Small trials report reduced oxidative stress markers and modest endurance improvements, with effect sizes described as small in trained athletes and larger in older or detrained populations.
  7. Healthy adult anti-aging (Weak). The case for asymptomatic healthy adults under 40 is mechanistically reasonable (replenishing age-related decline) but not directly RCT-validated for outcomes in this population.

How is CoQ10 dosed?

CoQ10 dosing depends on goal: general anti-aging maintenance is discussed at 100–200 mg/day; clinical conditions use 300–600 mg/day. The ubiquinol vs ubiquinone choice affects dose magnitude, since ubiquinol is more bioavailable and equivalent serum effects occur at roughly half the dose. Taking CoQ10 with fat is standard guidance, since CoQ10 is fat-soluble and absorption is meaningfully dependent on dietary lipid coadministration.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. General health / age-related maintenance. 100–200 mg/day ubiquinol (or 200–300 mg ubiquinone) with the largest meal — used by adults over 40 for age-related CoQ10 replenishment.
  2. Statin-induced muscle pain. 100–200 mg/day ubiquinol for 8–12 weeks as a tolerance trial, with continuation contingent on symptom improvement.
  3. Heart failure / cardiovascular adjunct. 300 mg/day ubiquinone (the Q-SYMBIO protocol) or 200 mg/day ubiquinol — a clinical-adjunct dose coordinated with a cardiologist, not a general-health dose.
  4. Fertility / mitochondrial disease / migraine. 300–400 mg/day, typically ubiquinol for older users — the dose range used in fertility trials and migraine prophylaxis studies.

Reported timeline: serum CoQ10 levels rise within days; tissue concentrations build over weeks; clinical effects emerge over 8–12 weeks. The Q-SYMBIO and KiSel-10 hard-endpoint effects took months to years to manifest; CoQ10 is discussed as a chronic-use supplement with no perceptible acute effect.

Label math. "CoQ10 200 mg" typically means 200 mg of either ubiquinone or ubiquinol — the label distinction matters. Ubiquinol is reported as roughly 2× more bioavailable than ubiquinone, so 100 mg ubiquinol is discussed as roughly comparable to 200 mg ubiquinone in serum terms.

How CoQ10 is taken

CoQ10 is taken orally as softgels (most common), capsules, tablets, or sometimes liquid. The dominant practical consideration reported is absorption — CoQ10 is highly fat-soluble, and absorption with food, especially fat-containing meals, is meaningfully better than empty-stomach dosing. Form choice (ubiquinol vs ubiquinone) is the second major decision.

AspectReported
FrequencyOnce daily for doses up to 200 mg; split twice daily (AM + PM) for higher doses (300 mg+) — reported to improve the serum profile over a single large dose.
Best time of dayWith the largest fat-containing meal of the day, typically breakfast or dinner.
FoodWith fat is standard guidance. CoQ10 absorption is reported to be meaningfully impaired without dietary fat coadministration, with empty-stomach dosing reported to waste a substantial portion of the dose.
FormSoftgels in an oil base are the common default given better absorption. Ubiquinol is used for adults over 40, statin users, and clinical contexts; ubiquinone is considered adequate for users under 35 with no impaired-conversion factors.
Standardization markerA label reading "Kaneka ubiquinol" (a pharmaceutical-grade ubiquinol manufacturer) or USP-grade ubiquinone with mg per serving explicitly disclosed is the clearer standard.
CyclingNo cycling is reported as required — chronic daily use is the trial-validated model; the Q-SYMBIO protocol ran 2 years continuous and KiSel-10 ran 4 years.

What does CoQ10 stack with?

CoQ10 is discussed alongside the broader mitochondrial-bioenergetics and cardiovascular toolkit. The mechanism — mitochondrial electron transport plus membrane antioxidant — is reported as complementary to peptides operating on mitochondrial biogenesis (MOTS-c), NAD+ supply (NAD+ peptide), and other longevity-stack components.

With peptides

CoQ10 is discussed alongside the mitochondrial peptide cluster. MOTS-c is reported to activate AMPK, improve insulin sensitivity, and support mitochondrial biogenesis at the regulatory/genetic level. NAD+ peptide delivers NAD+, the cofactor for sirtuins and the electron donor for Complex I of the electron transport chain. CoQ10 operates at a different layer — the electron carrier between Complex I/II and Complex III, plus a fat-soluble antioxidant for mitochondrial membranes. The three converge on mitochondrial function from different angles, with no known negative interaction documented in the sources reviewed for this page.

With supplements

  1. NMN — an oral NAD+ precursor, discussed as pairing cleanly with CoQ10's electron-transport mechanism, both supporting mitochondrial ATP production from different angles.
  2. Spermidine — an autophagy and mitophagy activator, reported to clear damaged mitochondria while CoQ10 supports the remaining functional ones.
  3. Omega-3 fish oil — cardiovascular and membrane fluidity support, a common co-occupant in cardiovascular supplement protocols.
  4. Selenium (200 mcg/day) — the KiSel-10 trial used CoQ10 plus selenium combined; for cardiovascular-outcomes use, selenium is discussed as the evidence-paired adjunct.
  5. Resveratrol — a sirtuin activator and antioxidant, a compatible longevity-stack co-occupant.
  6. Magnesium — a cofactor for enzymes including those in mitochondrial energy metabolism.

With lifestyle factors

  1. Fat-containing meals. CoQ10 absorption is meaningfully fat-dependent; dosing with the largest fat-containing meal of the day is standard guidance.
  2. Regular endurance exercise. Exercise is reported to increase CoQ10 demand and may amplify benefit; CoQ10 is reported to reduce exercise-induced oxidative stress in some trials.
  3. Statin coordination. For users on a statin, CoQ10 supplementation is discussed as a reasonable case-by-case adjunct decision, particularly with muscle symptoms present.
  4. Anticoagulation monitoring. For users on warfarin, monitoring INR for the first 4–6 weeks of CoQ10 use is standard guidance given the documented modest interaction.

Side effects and interactions

CoQ10 has one of the cleaner safety profiles of any cardiovascular supplement reviewed for this site — decades of clinical use, no established Tolerable Upper Intake Level, and no documented serious adverse events at supplemental doses in the sources reviewed. The main considerations reported are mild GI effects, blood-pressure-lowering at high doses, and the warfarin interaction.

Common (mostly transient)

  1. Mild GI discomfort — occasional nausea or stomach upset, especially on an empty stomach, reported to resolve with food coadministration.
  2. Heartburn or reflux — uncommon, occasionally reported at higher doses (300 mg+).
  3. Mild fatigue or dizziness — rare, typically dose-related.
  4. No documented serious adverse events at supplemental doses across the human RCT base reviewed, reflecting decades of use.

Less common (watch-list)

  1. Mild blood-pressure reduction — relevant for users on antihypertensive medications given a modest additive effect; BP monitoring during the first 4–6 weeks of use is standard guidance.
  2. Insomnia — occasionally reported with evening dosing; switching to a morning dose is a common mitigation.

Drug and supplement interactions

  1. Warfarin. CoQ10 has structural similarity to vitamin K and can mildly reduce warfarin's anticoagulant effect. A modest but documented interaction; INR monitoring during the first 4–6 weeks of combined use is standard guidance. Newer anticoagulants (apixaban, rivaroxaban) do not have this interaction.
  2. Statins. No negative interaction is reported — statins deplete CoQ10, and CoQ10 supplementation may mitigate statin myopathy, generally regarded as a beneficial coadministration.
  3. Antihypertensive medications. CoQ10 modestly lowers blood pressure, with an additive effect alongside BP medications; monitoring during titration is standard guidance.
  4. Chemotherapy — some cancer treatments (doxorubicin) deplete CoQ10, and supplementation may protect cardiac function; oncologist coordination is standard guidance.
  5. Pregnancy — data is limited; clinician coordination is standard guidance for supplemental dosing during pregnancy.

What isn't established about CoQ10

CoQ10 has one of the deeper supplement evidence bases in cardiovascular and statin-myopathy contexts reviewed for this site. Several open questions remain, particularly around population specificity, optimal form (ubiquinol vs ubiquinone), and the benefit gap between clinical and healthy populations.

Healthy-adult primary prevention. The strongest CoQ10 evidence reviewed is in established heart failure, cardiovascular disease, and statin myopathy populations. Whether CoQ10 prevents cardiovascular events in metabolically healthy adults is much less directly studied. The KiSel-10 trial in elderly Swedish adults provides some primary-prevention signal, but the evidence base in healthy adults under 65 is thin.

Ubiquinol vs ubiquinone head-to-head outcomes. Ubiquinol is more bioavailable, particularly in older adults, but the major outcome trials (Q-SYMBIO, KiSel-10) used ubiquinone. Whether ubiquinol produces larger outcome effects at equivalent serum levels is mechanistically reasonable but not directly RCT-tested for hard endpoints in the sources reviewed.

Statin-myopathy efficacy variability. Banach et al. 2015's meta-analysis is positive; other reviews are more cautious. Not all statin users with muscle symptoms are reported to respond to CoQ10, and whether the responder subgroup can be identified ahead of time is not resolved.

Neurodegenerative diseases. The mechanistic case is discussed as strong (mitochondrial dysfunction is implicated in Parkinson's, Huntington's, ALS), but clinical trial results have been mixed to disappointing. Whether higher doses, different formulations, or earlier intervention would change this is open.

Optimal dose-response curve. The Q-SYMBIO 300 mg arm produced the cardiac outcomes reported. Whether higher doses (600–1200 mg) produce additional clinical benefit is not well characterized in the sources reviewed.

Multi-year safety at high doses. Q-SYMBIO ran 2 years at 300 mg/day; KiSel-10 ran 4 years at 200 mg/day. Multi-decade use at 400+ mg/day is not characterized in controlled trials reviewed, though the safety profile of long-term moderate dosing is reassuring.

Product-quality considerations

CoQ10 is widely available over-the-counter from supplement retailers. Quality is reported to vary considerably, particularly around form (ubiquinol vs ubiquinone), oil-base formulation for absorption, and dose disclosure.

Quality markers reported in the category

  • Kaneka ubiquinol or Kaneka Q10 — a pharmaceutical-grade CoQ10 manufacturer whose trademarks signal trial-relevant raw material.
  • Softgels in oil base — reported to have meaningfully better absorption than dry capsules or tablets for fat-soluble CoQ10.
  • Form explicitly disclosed — "ubiquinol" (reduced, more bioavailable) or "ubiquinone" (oxidized, less bioavailable but cheaper), with ubiquinol generally preferred for adults over 40 and statin users.
  • 100–200 mg per serving as a practical baseline dose; higher doses for clinical use are coordinated with a clinician.
  • Third-party testing — USP, NSF, or ConsumerLab certification signals independent verification.
  • cGMP-certified manufacturing facility.
  • No proprietary blends that obscure the actual CoQ10 dose alongside fillers.
  • Cool, light-protected storage — CoQ10 is reported to degrade with prolonged exposure to heat and light.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

CoQ10 FAQ

How do ubiquinol and ubiquinone compare?

Ubiquinol (the reduced, active antioxidant form) is reported as meaningfully better absorbed than ubiquinone (the oxidized form), particularly in adults over 40 and in users with conditions that impair the conversion (statin therapy, chronic disease, mitochondrial dysfunction). For users under 35 with no metabolic concerns, ubiquinone is generally considered adequate, since conversion is efficient at that age. The Q-SYMBIO heart failure trial used ubiquinone successfully at 300 mg/day; ubiquinol trials tend to use lower doses (100–200 mg) for similar serum effects, given its higher bioavailability.

Is CoQ10 discussed as necessary for everyone on a statin?

It is generally treated as a case-by-case decision. Statins inhibit HMG-CoA reductase — the same enzyme upstream of endogenous CoQ10 synthesis — so chronic statin use is reported to reduce CoQ10 levels. Whether this depletion meaningfully contributes to statin-induced myopathy (muscle pain) is debated; some trials report CoQ10 supplementation reduces statin myopathy, others report no effect. A common practical approach: for users on a statin experiencing muscle pain or weakness, a trial of 100–200 mg/day ubiquinol for 8–12 weeks is low-risk, with continuation contingent on symptom improvement.

Does CoQ10 help heart failure?

Yes, in the published trial base, with meaningful effect sizes. The Q-SYMBIO trial (Mortensen et al. 2014, n=420, 2-year follow-up) reports 300 mg/day CoQ10 significantly reduced major adverse cardiovascular events and cardiovascular mortality versus placebo in chronic heart failure patients. The KiSel-10 study (Alehagen et al. 2013) reports CoQ10 plus selenium combined reduced cardiovascular mortality by 54% in elderly Swedish adults over 4 years. These are discussed as among the stronger published cardiovascular-mortality outcome trials for any supplement.

How long does it take to notice an effect from CoQ10?

Subjective effects, if any, are reported to emerge gradually over 4–8 weeks. CoQ10 is not acute like caffeine; serum CoQ10 levels build over weeks of consistent dosing, and tissue concentrations follow more slowly. The clinical trials reviewed measured outcomes over 6 months to 4 years. For cardiac or statin-myopathy use, evaluation at the 8–12 week mark rather than the 2-week mark is standard guidance. For general anti-aging or longevity use, the effects are discussed as mostly biomarker-grade rather than subjectively perceptible.

Does CoQ10 stack with MOTS-c or NAD+ peptides?

The mechanism layering is discussed as natural for users targeting mitochondrial function. MOTS-c is a mitochondrial-derived peptide reported to activate AMPK, increase insulin sensitivity, and support mitochondrial biogenesis at the genetic/regulatory level. NAD+ peptide delivers the essential cofactor for sirtuins and mitochondrial complex I activity. CoQ10 works at a different layer — it is the electron carrier between Complex I/II and Complex III in the electron transport chain, plus a fat-soluble antioxidant for mitochondrial membranes. The three are discussed as converging on mitochondrial bioenergetics from different angles, with no known negative interaction documented in the sources reviewed for this page.

What dose of CoQ10 is discussed for different goals?

The dose discussed depends on goal. For general health and age-related CoQ10 decline (over 40): 100–200 mg/day of ubiquinol or 200–300 mg of ubiquinone. For statin-induced muscle pain: 100–200 mg/day ubiquinol. For heart failure or established cardiovascular disease as a clinical adjunct (coordinated with a cardiologist): 300–600 mg/day, the Q-SYMBIO dose range. For mitochondrial disease, fertility (egg/sperm quality), or migraine prophylaxis: 300–400 mg/day. Doses above 600 mg/day rarely add reported clinical benefit.

Does CoQ10 improve sperm or egg quality?

Reasonable trial evidence supports this in both male and female fertility contexts. Multiple trials report CoQ10 supplementation improves sperm motility and concentration in subfertile men (200–400 mg/day for 3–6 months). Female fertility evidence is smaller but suggests improved ovarian response in older reproductive-age women, particularly during IVF cycles. The mechanism discussed is mitochondrial, since both eggs and sperm are exceptionally energy-demanding cells sensitive to mitochondrial function.

Is CoQ10 compatible with warfarin?

Clinician coordination is standard guidance — CoQ10 has a structural similarity to vitamin K and can mildly reduce warfarin's anticoagulant effect. The interaction is described as modest but real, with INR monitoring the practical safeguard. Most patients can remain on both with appropriate INR adjustment; some prescribers prefer to avoid the combination. Newer anticoagulants (apixaban, rivaroxaban) do not carry this interaction.

References

  1. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641-649. https://pubmed.ncbi.nlm.nih.gov/25282031/
  2. Alehagen U, Johansson P, Björnstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial. Int J Cardiol. 2013;167(5):1860-1866. https://pubmed.ncbi.nlm.nih.gov/22626835/
  3. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24-34. https://pubmed.ncbi.nlm.nih.gov/25440725/
  4. Lafuente R, González-Comadrán M, Solà I, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet. 2013;30(9):1147-1156. https://pubmed.ncbi.nlm.nih.gov/23912751/
  5. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 supplementation in aging and disease. Front Physiol. 2018;9:44. https://pubmed.ncbi.nlm.nih.gov/29459830/
  6. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713-715. https://pubmed.ncbi.nlm.nih.gov/15728298/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

JACC Heart Failure · 2014Open Access
The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results from Q-SYMBIO →

Mortensen SA, Rosenfeldt F, Kumar A, et al.

A 2-year multicenter randomized double-blind placebo-controlled trial of CoQ10 (300 mg/day, ubiquinone) in 420 patients with moderate-to-severe chronic heart failure (NYHA III-IV). Reports CoQ10 significantly reduced major adverse cardiovascular events (MACE) and cardiovascular mortality versus placebo, with parallel improvements in symptom severity. The largest and most-cited outcome trial for CoQ10 in heart failure.

International Journal of Cardiology · 2013Open Access
Cardiovascular Mortality and N-Terminal-proBNP Reduced After Combined Selenium and Coenzyme Q10 Supplementation: A 5-Year Prospective Randomized Double-Blind Placebo-Controlled Trial →

Alehagen U, Johansson P, Björnstedt M, et al.

The KiSel-10 trial — a 4-year randomized double-blind placebo-controlled trial of CoQ10 (200 mg) plus selenium (200 mcg) in 443 elderly Swedish adults aged 70–88. Reports the combination significantly reduced cardiovascular mortality by 54% and NT-proBNP biomarker versus placebo over the follow-up period.

Mayo Clinic Proceedings · 2015Open Access
Effects of Coenzyme Q10 on Statin-Induced Myopathy: A Meta-Analysis of Randomized Controlled Trials →

Banach M, Serban C, Sahebkar A, et al.

A meta-analysis of RCTs of CoQ10 supplementation in statin-associated muscle symptoms. Reports the pooled analysis found significant reductions in muscle pain, muscle weakness, muscle cramps, and muscle tiredness with CoQ10 supplementation versus placebo, with effect sizes described as modest.

Frontiers in Physiology · 2018Open Access
Coenzyme Q10 Supplementation in Aging and Disease →

Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P

A comprehensive review of CoQ10 biology and supplementation evidence across cardiovascular disease, neurodegenerative diseases (Parkinson's, Huntington's, ALS), mitochondrial diseases, statin myopathy, fertility, and chronic fatigue, including the ubiquinone-vs-ubiquinol bioavailability question and dose-response relationships.

Journal of Assisted Reproduction and Genetics · 2013Open Access
Coenzyme Q10 and Male Infertility: A Meta-Analysis →

Lafuente R, González-Comadrán M, Solà I, et al.

A meta-analysis of RCTs of CoQ10 supplementation in men with idiopathic infertility. Reports CoQ10 significantly improved sperm concentration, motility, and morphology versus placebo, with effect sizes modest but consistent across trials.

MitochondriaHeart FailureStatin SupportUbiquinolElectron TransportFertility

Related Supplements

NMNNAD+SpermidineResveratrolFish OilMagnesium

Supplement brands

  • VitaTurbo: 1 product whose label lists it as the main active

We may earn commissions from peptide vendor affiliate links.

Have a question about CoQ10? Send us an email